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Basophils as Key Regulators of Allergic Inflammation
and Th2-type Immunity
Bernhard F. Gibbs
Abstract: Basophils have long been suspected as playing more than a
bystander role in initiating and maintaining allergic disorders, despite
their relatively low numbers compared with other effector cells, such
as mast cells and eosinophils. In vitro studies clearly demonstrated
their propensity to generate proallergic cytokines, such as interleukin
4 and interleukin 13, as well as histamine and leukotrienes after
simulation with allergens and innate IgE-dependent triggers. How-
ever, only very recently have mouse basophils been identiﬁed as key
regulators of allergy in vivo, including orchestrating Th2 immunity to
protease allergens in the induction phase. This review highlights these
exciting advances that go far in unraveling our understanding of
basophil function in the orchestration of allergic inﬂammation.
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Compared with other allergic effector cells, basophils arerelatively rare and constitute only 1% or less of circulating
leukocytes. Like their tissue-ﬁxed mast cell counterparts,
basophils express high-afﬁnity immunoglobulin E (IgE)
receptors (FcDRI), secrete histamine and eicosanoids (primar-
ily LTC4) after IgE-mediated provocation, and undergo
metachromatic staining. However, before the emergence of
basophil-speciﬁc markers, it was hard to demonstrate their
presence in organs affected by allergic inﬂammation. Despite
this, in the early 1990s, indirect evidence pointed to their
presence in these tissues during late-phase reactions based on
their ability to release histamine without concomitant
prostaglandin D2 (PGD2) or mast cell tryptase.
1,2 These
observations increased interest in basophils as allergic effector
cells, but during this period, few could have foreseen the
crucial functions of these cells in actually orchestrating
allergic inﬂammatory events, let alone possibly helper T cell
type 2 (Th2) immunity itself.
A major turning point that changed our perceptions of
allergic effector cells per se was the discovery that mast cells
produce a variety of inﬂammatory and immunomodulatory
cytokines. Murine mast cells or tumorigenic mast cell lines, in
particular, were found to generate interleukin 1 (IL-1), IL-3,
IL-4, IL-5, IL-6, IL-8, IL-13, granulocyte macrophage colony-
stimulating factor, and tumor necrosis factor-> (TNF->)
besides several others after IgE-dependent activation3
(reviewed in Gordon et al4). It was shown that mast cells
could potentially drive developing helper T cell responses as
well as up-regulate adhesion molecules on endothelial cells
responsible for attracting other allergic inﬂammatory cells.5Y7
However, unlike rodent mast cells, the ability of primary
human mast cells from either the lung or skin to generate Th2-
type cytokines (especially IL-4) seems to be rather limited.8Y11
In contrast, human basophils rapidly synthesize and release
IL-4,12Y15 in some cases even from preformed stores,15 and IL-
13,15Y17 cytokines that play a crucial role in supporting
underlying atopy.
Although human basophils share certain characteristics
with their mast cell counterparts, they differ in a number of
important aspects regarding their ability to react to various
stimuli and the types of mediators they release (Fig. 1). In
terms of cytokine synthesis, human basophils are relatively
constrained to generating IL-4 and IL-13 rather than IL-5 or
the multitude of proinﬂammatory cytokines ascribed to mast
cells.18 This sets the scene for the emergence of the basophil as
a potential supporter of Th2 responses, evidence of which is
highlighted in this review.
BASOPHILS ARE MAJOR SOURCES OF IL-4 AND
IL-13 AND ARE RECRUITED TO TISSUES
AFFECTED BY ALLERGIC INFLAMMATION
Basophils express a wide variety of chemokine receptors
(eg, CCR1-3, CXCR1, CXCR3, and CXCR4) and also
respond to a range of chemokines and cytokines that facilitate
their migration.19,20 In recent years, the basophil-speciﬁc BB1
and 2D7 antibodies have been used with great success to
demonstrate the presence of basophils in various tissues
affected by allergic disease, such as the lung, skin, and nose
(reviewed in Falcone et al21). During allergen-induced
asthmatic reactions, basophils were shown to be responsible
for 72% of IL-4 protein in the bronchial mucosa,22 an
observation that also correlates to murine asthma models.23 In
another study, Devouassoux and coworkers24 demonstrated
that the early production of IL-4 and IL-13 in the peripheral
blood of asthmatic patients after allergen challenge was
exclusively basophil derived. A real-time quantitative poly-
merase chain reactionYbased assay in whole blood also
identiﬁes basophils as the most prominent source of IL-4
and IL-13 after stimulation with the cat allergen Fel d1.25
These ﬁndings veriﬁed the earlier in vitro investigations
(described previously) showing that basophils are geared to
rapid generation of these cytokines.
Interleukin 4 and IL-13 are archetypal proallergic
cytokines. They increase vascular cell adhesion molecule-1
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expression on the microvascular endothelium and eotaxin
synthesis from airway epithelial cells, supporting leukocyte
inﬂux into affected tissues during late-phase responses.26Y28
They also play a key role in B-cell immunoglobulin class
switching to favor IgE synthesis, and IL-4 is a vital factor for
the early differentiation of CD4+ lymphocytes to a Th2 type
(reviewed in Haas et al29).
Given that basophils are major producers of these
cytokines, an immunomodulatory role in supporting the
previously mentioned events by these cells seems highly
plausible (Fig. 2). However, direct in vivo evidence for this
has been, until very recently, scarce, owing largely to a lack
of basophil knockout animal models because a basophil-
speciﬁc growth factor has not yet been identiﬁed. Although
growth factors such as IL-3, in particular, promote basophil
development from CD34+ progenitors (and controversially,
murine mast cells, but not human mast cells), basophils are
still present in IL-3Ydeﬁcient mice.30 This has stiﬂed the
development of basophil-knockout models analogous to
mast cellYdeﬁcient mice (lacking c-kit receptors or c-kit
ligand/stem cell factor, mandatory for mast cell matura-
tion). To circumvent this problem, basophil-speciﬁc mono-
clonal antibodies have been used to deplete circulating
murine basophils,31 a technique that could potentially re-
volutionize future investigations into unraveling their bio-
logical roles.
BASOPHILS REGULATE LATE-PHASE REACTIONS
AND CHRONIC ALLERGIC INFLAMMATION
Although murine mast cells can readily produce the Th2-
type cytokines ascribed to human basophils, implying a
redundancy in function for the latter, it is remarkable that
some of the strongest evidence for a major role of basophils in
allergic inﬂammation comes from murine allergy models. One
suchmodel uses transgenic mice generating 2,4,6-trinitrophenol
(TNP)Yspeciﬁc IgE that gives rise to a variety of allergic
responses after subcutaneous TNP injection.32 This consists
of early- and late-phase allergic responses, chronic allergic
inﬂammation, and anaphylaxis after intravenous TNP injec-
tion. It was demonstrated that these mice fail to display signs
of chronic allergic inﬂammation after prior depletion of
circulating basophils.31 Furthermore, a combinational
approach, using a range of mice genetically defective in
various lymphocytes and mast cells and reconstitution
experiments, showed that mast cells, T cells, and natural
FIGURE 1. Summary of humanmast cell and basophil heterogeneity to stimulation andmediator generation (for better clarity, this is not
a comprehensive list). Although both cell types react to IgE-mediated triggers, ionophores, basophils are more reactive to fMLP and C3a
than most human mast cell types. Conversely, connective tissue mast cells (MCTC), but not mucosal mast cells (MCT) or basophils, are
stimulated by neuropeptides and polybasic amines. In terms of mediator secretion, both cells secrete histamine and LTC4. Mast cells
additionally release tryptase as well as, in the case of MCTC, chymase and PGs (primarily PGD2). Human basophils and mast cells differ in
terms of cytokine synthesis: basophils are more restricted to IL-4 and IL-13 generation, whereas isolatedmast cells produce TNF-a and IL-8
in vitro, although this may not reﬂect in vivo settings. Basophils are also known to respond to a large number of growth factors and
chemokines that dramatically enhance their ability to generate mediators after IgE-dependent triggering. Humanmast cells, on the other
hand, are generally only responsive to priming by stem cell factor (SCF) and, to some extent, by IL-4 and IL-6. GM-CSF indicates
granulocyte macrophage colony-stimulating factor; RANTES, regulated on activation normally T-cell expressed and secreted.
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killer cells (NK) and natural killer T cells (NKT) were not
necessary for the late-phase allergic reactions, in stark
contrast to basophils.33
BASOPHILS AS POTENTIAL MODULATORS
OF LOCAL IgE SYNTHESIS
Recently, it has been shown that B cells residing in the
bronchial mucosa of asthmatic patients undergo class switch-
ing to IgE synthesis, supporting earlier observations regarding
their local generation of allergen-speciﬁc IgE in the nasal
mucosa.34 Gould et al35 calculated that this local IgE
production may account for a substantial portion of IgE
saturating allergic effector cells within these sites. The fact that
IgE synthesis occurs not only in the lymph nodes but locally
within organs affected by allergic inﬂammation permits
immunomodulatory input from resident allergic effector cells
such as basophils.
Immunoglobulin E class switching is controlled by IL-4,
IL-13, and CD40 ligand (CD40L) binding to its counterpart
receptor on B cells. Yanagihara et al36 showed that basophils
can indeed direct polyclonal IgE synthesis in vitro by virtue of
their ability to produce the previously mentioned stimuli, the
effects of which were inhibited by the addition of neutralizing
antibodies against IL-4, IL-13, and CD40L. In sharp contrast,
cord bloodYderived human mast cells failed to elicit this
response. This is in agreement with an earlier study showing
that although basophils (either primary or KU812 cell lines)
and human mast cells (HMC-1) expressed CD40L, mast cells
could only stimulate B-cell IgE synthesis in the presence of
exogenously applied IL-4.37 Although these observations have
yet to be fully veriﬁed by in vivo investigations, the liaison
between tissue-associated basophils and B cells certainly
represents a plausible circulus vitiosus of increasing IgE and
effector cell sensitization central to the pathophysiology of
allergic disease.
DO BASOPHILS CONTROL Th2 IMMUNITY?
As already discussed, it is increasingly clear that
basophils are the main early source of IL-4 after allergen
exposure in peripheral blood and asthmatic airways. Unlike
IL-13, IL-4 is unique in driving CD4+ T cells to a Th2
phenotype, which subsequently produce IL-4, IL-13, and other
Th2-type cytokines themselves (reviewed in Haas et al29). The
importance of IL-4 in initiating Th2 development was
conﬁrmed by studies showing that mice lacking either IL-
4R> or Stat6 (which controls IL-4Ydirected signaling) do not
generate Th2 immune responses.38,39 In addition to governing
chronic allergic inﬂammation and perhaps also IgE synthesis,
basophil-derived IL-4 may thus play a role in controlling Th2
immunity too. At the very least, basophils may exacerbate
existing Th2 polarization in ongoing allergic disease. Further
evidence for an association between basophils and Th2
lymphocytes is given by clinical studies showing that speciﬁc
allergen immunotherapy reduces basophil reactivity and
numbers as well as Th2 immunity.40
Although there is strong evidence to show that basophils
are capable of supporting local Th2 immune responses at sites
of allergic inﬂammation and possibly regulating local B-cell
IgE class switching, several important issues remain. First, do
basophils migrate to the lymph nodes, which are the prime
tissue sites for developing immune responses? Second, do
basophils participate in the induction phase of Th2 immunity?
The latter would require basophils to be activated by
mechanisms that do not require the presence of surface-
bound antigen-speciﬁc IgE.
FIGURE 2. Simpliﬁed overview of the immunomodulatory roles of basophils. APC indicates antigen-presenting cells.
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Basophils are not usually attributed to being present in
the lymph nodes. However, a recent study has clearly
demonstrated that they transiently migrate into the draining
lymph nodes of mice after immunization with the protease
allergen, papain.41 Interestingly, these investigations also
showed that basophils were activated by protease allergen by
innate triggering and released Th2 cytokines that were
essential for initiating Th2 differentiation. A considerable
proportion of activated basophils within the lymph nodes also
released thymic stromal lymphopoietin (TSLP), in addition to
IL-4, and were the only cell type within the lymph nodes that
produced this Th2-driving factor. The TSLP-neutralizing
antibodies indeed diminished Th2 differentiation without
affecting either dendritic cell maturation and migration or
basophil accumulation within the draining lymph nodes. This
report clearly suggests that mouse basophils play a vital role in
innate immune recognition leading to Th2 responses by
secreting IL-4 and TSLP.
Although the previously mentioned data add further
credence to the immunomodulatory capabilities of basophils,
there are a number of unresolved issues. For example, TSLP
production in human basophils has not yet been reported, and
there is contradictory evidence regarding their ability to react
to speciﬁc protease-activated receptor agonists42 versus
protease allergens (eg, Der p1).43 Elucidating the mechanisms
of basophil migration into the lymph nodes after protease
allergen challenge and whether this migration takes place in
other settings also need addressing. For instance, although
basophils have been shown to be critical in recruiting Th2 cells
into affected tissues after Nippostrongylus brasiliensis infec-
tion (which also causes a substantial Th2-type response),44
their innate activation was not necessary for Th2 differentia-
tion in the lymph nodes.45 Thus, although the evidence for
basophil-directed immunomodulation within organs such as
the lung is strong, their ability to control Th2 immunity, as
well as IgE class switching, within lymphatic tissues is by no
means fully resolved. This applies both to their ability to
participate in early (innate) events of conditioning Th2
responses and to ongoing allergic disease, where their role
in the lymphatic tissues is also not known.
INNATE ACTIVATORS OF BASOPHIL
CYTOKINE SYNTHESIS
There is now a wealth of literature showing that human
basophils produce IL-4 and IL-13 in nonsensitized individuals
by various innate triggers, some of which cause activation of
FcDRI by binding to IgE in a nonYantigen-speciﬁc manner
(reviewed in Falcone et al21,46). These include parasitic antigens
(eg, Schistosoma mansoni, Echinococcus multilocularis),
lectins (eg, concanavalin A), and viral superantigens (eg,
human immunodeﬁciency virus 1 gp120) that activate basophils
by binding to nonYantigen-speciﬁc IgE antibodies. Further-
more, basophil cytokine release is also caused by engagement
of certain leukocyte immunoglobulinlike receptors (eg, LIR7),
toll-like receptors (eg, TLR2), and to a more limited extent, by
C5a/C3a and formyl-methionyl-leucyl-phenylalanine (fMLP).
In addition to the previously mentioned innate stimuli,
basophil growth factors such as IL-3 and nerve growth factor
(NGF) can also induce considerable levels of Th2-type
cytokine synthesis.47,48 Although this usually occurs only at
relatively high concentrations of either IL-3 or NGF (above 10
ng/mL), lower amounts (1 ng/mL) substantially enhance IgE-
dependent basophil mediator release to both speciﬁc allergens
and innate activators. Regarding NGF, there is compelling
evidence to suggest that this neurotrophin participates in both
animal models of allergy and in human allergic asthma, where
it correlates with disease severity and IgE levels.49,50 Because
basophils from asthmatic donors display a hyperreleaser
phenotype,51 factors such as NGF may have an important
function in enhancing the synthesis of basophil-derived Th2-
type cytokines and thereby their proallergic immunomodula-
tory roles (Fig. 2).
BASOPHILS AS TARGETS FOR
ANTIALLERGIC THERAPY
Given their potential in supporting both allergic
inﬂammation and underlying Th2 immunity, basophils are
an attractive target for antiallergic therapy. Their abilities to
release mediators are inhibited by certain existing antiallergic
agents such as glucocorticoids, methylxanthines, and calci-
neurin inhibitors, and this may partially explain their clinical
effectiveness. Other traditional therapeutic agents, such as
cromoglycate, have no known effects on basophils and highly
variable actions on various mast cell subtypes.
The well-known limitations of these agents, including
their heterogeneous actions on basophils and mast cells, have
prompted renewed attempts to block allergen-mediated FcDRI
activation of these cells. One promising approach is to prevent
free IgE antibodies from binding to FcDRI using monoclonal
anti-IgE (omalizumab), which reduces both effector cell
sensitization and FcDRI expressions. Treatment with omali-
zumab in allergic rhinitis patients has been shown to strikingly
reduce basophil reactivity and lead to a rapid decline in FcDRI
expression, which was faster in comparison to mast cells.52 In
parallel, these authors also observed a reduction in allergen-
induced wheal size. A similar decline in basophil reactivity
after omalizumab therapy is seen in allergic asthma, although
in these settings, this was not always matched by clinical
improvement.53
Basophils may also be directly affected by rush
desensitization regimens, which has been ascribed to a loss
of Syk expression,54 a crucial stimulatory signal associated
with FcDRI activation. But their signal transduction machinery
additionally encompasses a range of inhibitory signals that
may contribute to their functional desensitization. One such
signaling target is the src homology 2 domainYcontaining
inositol 5oˆphosphatase (SHIP), an inhibitory enzyme that is
centrally involved in IgE-mediated signaling in both baso-
phils and mast cells.55Y57 The SHIP has been shown to be
mobilized upon the activation of inhibitory receptors, such as
IRp60 (CD300a), leading to a dramatic reduction in allergic
effector cell function.58 CD300a, CD200R,59 Siglec-8,60 and
FcFRIIb (the latter only blocks basophil responses in
conjunction with FcDRI coYcross-linking61) up-regulate
SHIP expressions and may in the future be exploited for
antiallergic therapies.
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CONCLUSIONS
Recent in vivo investigations have provided exciting
new inroads that support earlier in vitro studies showing that
basophils are far from mere bystander cells of allergy and
Th2 immunity. Their propensity to rapidly deliver Th2
cytokines under a variety of conditions and their necessity in
eliciting chronic allergic inﬂammation underlines their
immunomodulatory potential. However, the details concern-
ing these actions still need to be elucidated, also in view of
input from regulatory T cells that may down-regulate
proallergic responses after parasitic helminth infections.
The physiological purpose of basophils also remains elusive,
as well as their interactions with other effector cells of the
allergic inﬂammatory response. Nonetheless, there is over-
whelming evidence to show that basophils contribute to the
symptoms of allergic disease and support underlying Th2
immunity, especially in ongoing allergy. This cell therefore
poses an obvious therapeutic target, and identifying ligands
for inhibitory receptor engagement may be a promising
approach to generate new antiallergic therapies.
REFERENCES
1. Lichtenstein LM, Bochner BS. The role of basophils in asthma. Ann N Y
Acad Sci. 1991;629:48Y61.
2. Atkins PC, Schwartz LB, Adkinson NF, von Allmen C, Valenzano M,
Zweiman B. In vivo antigen induced cutaneous mediator release:
simultaneous comparisons of histamine, tryptase, and prostaglandin D2
release and the effect of oral corticosteroid administration. J Allergy Clin
Immunol. 1990;86:360Y370.
3. Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S, Wilson SD,
et al. Interleukin 3Ydependent and Yindependent mast cells stimulated with
IgE and antigen expressmultiple cytokines. J ExpMed. 1989;170:245Y257.
4. Gordon JR, Burd PR, Galli SJ. Mast cells as a source of multifunctional
cytokines. Immunol Today. 1990;11:458Y464.
5. Huels C, Germann T, Goedert S, Hoehn P, Koelsch S, et al. Co-activation
of naive CD4+ T cells and bone marrowYderived mast cells results in the
development of Th2 cells. Int Immunol. 1995;7:525Y532.
6. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human
dermal mast cells contain and release tumor necrosis factor alpha, which
induces endothelial leukocyte adhesion molecule. Proc Natl Acad Sci
U S A. 1991;88:4220Y4224.
7. Meng H, Tonnesen MG, Marchese MJ, Clark RA, BahouWF, Gruber BL.
Mast cells are potent regulators of endothelial cell adhesion molecule
ICAM-1 and VCAM-1 expression. J Cell Physiol. 1995;165:40Y53.
8. Gibbs BF, Wierecky J, Welker P, Henz BM, Wolff HH, Grabbe J. Human
skin mast cells release preformed and newly generated TNF-alpha and
IL-8 but not IL-4, IL-5 or IL-13 following stimulation with anti-IgE and
other secretagogues. Exp Dermatol. 2001;10:312Y320.
9. Gibbs BF, Arm JP, Gibson K, Lee TH, Pearce FL. Human lung mast cells
release small amounts of interleukin-4 and tumour necrosis factor-alpha
in response to stimulation by anti-IgE and stem cell factor. Eur J
Pharmacol. 1997;327:73Y78.
10. Okayama Y, Petit-Fre´re C, Kassel O, Semper A, Quint D, et al.
IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung
mast cells. J Immunol. 1995;155:1796Y1808.
11. Schroeder JT, Kagey-Sobotka A, MacGlashan DW, Lichtenstein LM. The
interaction of cytokines with human basophils and mast cells. Int Arch
Allergy Immunol. 1995;107:79Y81.
12. Arock M, Merle-Be´ral H, Dugas B, Ouaaz F, Le Goff L, et al. IL-4 release
by human leukemic and activated normal basophils. J Immunol.
1993;151:1441Y1447.
13. Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils
primed by interleukin 3 (IL-3) produce IL-4 in response to
immunoglobulin E receptor stimulation. J Exp Med. 1993;177:605Y611.
14. MacGlashan DW, White JM, Huang SK, Ono SJ, Schroeder JT,
Lichtenstein LM. Secretion of IL-4 from human basophils. The
relationship between IL-4 mRNA and protein in resting and stimulated
basophils. J Immunol. 1994;152:3006Y3016.
15. Gibbs BF, Haas H, Falcone FH, Albrecht C, Vollrath IB, et al. Purified
human peripheral blood basophils release interleukin-13 and preformed
interleukin-4 following immunological activation. Eur J Immunol. 1996;
26:2493Y2498.
16. Ochensberger B, Daepp GC, Rihs S, Dahinden CA. Human blood
basophils produce interleukin-13 in response to IgE-receptor-dependent
and -independent activation. Blood. 1996;88:3028Y3037.
17. Li H, Sim TC, Alam R. IL-13 released by and localized in human
basophils. J Immunol. 1996;156:4833Y4838.
18. Schroeder JT, MacGlashan DW, Lichtenstein LM. Human basophils:
mediator release and cytokine production. Adv Immunol. 2001;77:
93Y122.
19. Marone G, Triggiani M, de Paulis A. Mast cells and basophils: friends as
well as foes in bronchial asthma? Trends Immunol. 2005;26:25Y31.
20. Iikura M, Miyamasu M, Yamaguchi M, Kawasaki H, Matsushima K,
et al. Chemokine receptors in human basophils: inducible expression
of functional CXCR4. J Leukoc Biol. 2001;70:113Y120.
21. Falcone FH, Zillikens D, Gibbs BF. The 21st century renaissance of the
basophil? Current insights into their role in allergic responses and innate
immunity. Exp Dermatol. 2006;15:855Y864.
22. Nouri-Aria KT, Irani AM, Jacobson MR, O’brien F, Varga EM, et al.
Basophil recruitment and IL-4 production during human allergen-
induced late asthma. J Allergy Clin Immunol. 2001;108:205Y211.
23. Luccioli S, Brody DT, Hasan S, Keane-Myers A, Prussin C, Metcalfe DD.
IgE(+), Kit(-), I-A/I-E(-) myeloid cells are the initial source of Il-4 after
antigen challenge in a mouse model of allergic pulmonary inflammation. J
Allergy Clin Immunol. 2002;110:117Y124.
24. Devouassoux G, Foster B, Scott LM, Metcalfe DD, Prussin C. Frequency
and characterization of antigen-specific IL-4Y and IL-13Yproducing
basophils and T cells in peripheral blood of healthy and asthmatic
subjects. J Allergy Clin Immunol. 1999;104:811Y819.
25. Ocmant A, Michils A, Schandene L, Peignois Y, Goldman M, Stordeur P.
IL-4 and IL-13 mRNA realtime PCR quantification on whole blood to
assess allergic response. Cytokine. 2005;31:375Y381.
26. Ying S, Meng Q, Barata LT, Robinson DS, Durham SR, Kay AB.
Associations between IL-13 and IL-4 (mRNA and protein), vascular cell
adhesion molecule-1 expression, and the infiltration of eosinophils,
macrophages, and T cells in allergen-induced late-phase cutaneous
reactions in atopic subjects. J Immunol. 1997;158:5050Y5057.
27. Li L, Xia Y, Nguyen A, Lai YH, Feng L, Mosmann TR, Lo D. Effects of
Th2 cytokines on chemokine expression in the lung: IL-13 potently
induces eotaxin expression by airway epithelial cells. J Immunol.
1999;162:2477Y2487.
28. Moore PE, Church TL, Chism DD, Panettieri RA, Shore SA. IL-13 and
IL-4 cause eotaxin release in human airway smooth muscle cells: a role for
ERK. Am J Physiol Lung Cell Mol Physiol. 2002;282:847Y853.
29. Haas H, Falcone FH, Holland MJ, et al. Early interleukin-4: its role in the
switch towards a Th2 response and IgE-mediated allergy. Int Arch Allergy
Immunol. 1999;119:86Y94.
30. Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, et al. Role for
interleukin-3 in mast-cell and basophil development and in immunity to
parasites. Nature. 1998;392:90Y93.
31. Obata K, Mukai K, Tsujimura Y, Ishiwata K, Kawano Y, et al. Basophils
are essential initiators of a novel type of chronic allergic inflammation.
Blood. 2007;110:913Y920.
32. Sato E, Hirahara K, Wada Y, Yoshitomi T, Azuma T, et al. Chronic
inflammation of the skin can be induced in IgE transgenic mice by means
of a single challenge of multivalent antigen. J Allergy Clin Immunol.
2003;111:143Y148.
33. Mukai K, Matsuoka K, Taya C, Suzuki H, Yokozeki H, et al. Basophils
play a critical role in the development of IgE-mediated chronic allergic
inflammation independently of T cells and mast cells. Immunity.
2005;23:191Y202.
34. Smurthwaite L, Walker SN, Wilson DR, Birch DS, Merrett TG, Durham
SR, Gould HJ. Persistent IgE synthesis in the nasal mucosa of hay fever
patients. Eur J Immunol. 2001;31:3422Y3431.
35. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, et al. The
biology of IGE and the basis of allergic disease. Annu Rev Immunol.
2003;21:579Y628.
36. Yanagihara Y, Kajiwara K, Basaki Y, Ikizawa K, Ebisawa M, et al.
WAO Journal & July 2008 Basophils in Allergy
* 2008 World Allergy Organization 127
Copyright @ 2008 World Allergy Organization. Unauthorized reproduction of this article is prohibited.
Cultured basophils but not cultured mast cells induce human IgE
synthesis in B cells after immunologic stimulation. Clin Exp Immunol.
1998;111:136Y143.
37. Gauchat JF, Henchoz S, Mazzei G, Aubrey J-P, Brunner T, et al. Induction
of human IgE synthesis in B cells by mast cells and basophils. Nature.
1993;365:340Y343.
38. Noben-Trauth N, Shultz LD, Brombacher F, et al. An interleukin 4
(IL-4)Yindependent pathway for CD4+ T cell IL-4 production is revealed
in IL-4 receptorYdeficient mice. Proc Natl Acad Sci U S A.
1997;94:10838Y10843.
39. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for
mediating responses to IL-4 and for development of Th2 cells. Immunity.
1996;4:313Y319.
40. Shim JY, Kim BS, Cho SH, Min KU, Hong SJ. Allergen-specific
conventional immunotherapy decreases immunoglobulin EYmediated
basophil histamine releasability. Clin Exp Allergy. 2003;33:52Y57.
41. Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the
initiation of allergen-induced T helper type 2 responses. Nat Immunol.
2007;9:310Y318.
42. Falcone FH, Morroll S, Gibbs BF. Lack of protease activated receptor
(PAR) expression in purified human basophils. Inflamm Res.
2005;54(suppl 1):S13YS14.
43. Phillips C, Coward WR, Pritchard DI, Hewitt CR. Basophils express a
type 2 cytokine profile on exposure to proteases from helminths and
house dust mites. J Leukoc Biol. 2003;73:165Y171.
44. Min B, Prout M, Hu-Li J, Zhu J, Jankovic D, et al. Basophils produce IL-4
and accumulate in tissues after infection with a Th2-inducing parasite.
J Exp Med. 2004;200:507Y517.
45. Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM. Type 2
immunity is controlled by IL-4/IL-13 expression in hematopoietic
non-eosinophil cells of the innate immune system. J Exp Med. 2006;
203:1435Y1446.
46. Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation
of its role in immune responses. Blood. 2000;96:4028Y4038.
47. Sin AZ, Roche EM, Togias A, Lichtenstein LM, Schroeder JT. Nerve
growth factor or IL-3 induces more IL-13 production from basophils of
allergic subjects than from basophils of nonallergic subjects. J Allergy
Clin Immunol. 2001;108:387Y393.
48. Gibbs BF, Zillikens D, Grabbe J. Nerve growth factor influences
IgE-mediated human basophil activation: functional properties and
intracellular mechanisms compared with IL-3. Int Immunopharmacol.
2005;5:735Y747.
49. Bonini S, Lambiase A, Angelucci F, Magrini L, Manni L, Aloe L.
Circulating nerve growth factor levels are increased in humans with
allergic diseases and asthma. Proc Natl Acad Sci U S A. 1996;93:
10955Y10960.
50. Braun A, Quarcoo D, Schulte-Herbruggen O, Lommatzsch M, Hoyle G,
Renz H. Nerve growth factor induces airway hyperresponsiveness in mice.
Int Arch Allergy Immunol. 2001;124:205Y207.
51. Gaddy JN, Busse WW. Enhanced IgE-dependent basophil histamine
release and airway reactivity in asthma. Am Rev Respir Dis. 1986;134:
969Y974.
52. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-
induced reductions in mast cell Fcepsilon RI expression and function.
J Allergy Clin Immunol. 2004;114:527Y530.
53. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release
decreases during omalizumab therapy in allergic asthmatics. Int Arch
Allergy Immunol. 2007;146:66Y70.
54. Kepley CL. Antigen-induced reduction in mast cell and basophil
functional responses due to reduced Syk protein levels. Int Arch Allergy
Immunol. 2005;138:29Y39.
55. Gimborn K, Lessmann E, Kuppig S, Krystal G, Huber M. SHIP
down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE
or antigen levels. J Immunol. 2005;174:507Y516.
56. Vonakis BM, Gibbons S Jr, Sora R, Langdon JM, MacDonald SM. Src
homology 2 domainYcontaining inositol 5¶ phosphatase is negatively
associated with histamine release to human recombinant
histamineYreleasing factor in human basophils. J Allergy Clin
Immunol. 2001;108:822Y831.
57. Gibbs BF, Rathling A, Zillikens D, Huber M, Haas H. Initial Fc epsilon
RI-mediated signal strength plays a key role in regulating basophil
signaling and deactivation. J Allergy Clin Immunol. 2006;118:
1060Y1067.
58. Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The
inhibitory receptor IRp60 (CD300a) is expressed and functional on
human mast cells. J Immunol. 2005;175:7989Y7995.
59. Shiratori I, Yamaguchi M, Suzukawa M, Yamamoto K, Lanier LL,
Saito T, Arase H. Down-regulation of basophil function by human
CD200 and human herpesvirus-8 CD200. J Immunol. 2005;175:
4441Y4449.
60. Yokoi H, Choi OH, Hubbard W, Lee HS, Canning BJ, et al. Inhibition
of FcepsilonRI-dependent mediator release and calcium flux from human
mast cells by sialic acidYbinding immunoglobulin-like lectin 8
engagement. J Allergy Clin Immunol. 2008;121:499Y505.
61. Kepley CL, Taghavi S, Mackay G, Zhu D, Morel PA, et al. Co-aggregation
of FcgammaRII with FcepsilonRI on human mast cells inhibits
antigen-induced secretion and involves SHIP-Grb2-Dok complexes.
J Biol Chem. 2004;279:35139Y35149.
Gibbs WAO Journal & July 2008
128 * 2008 World Allergy Organization
